Free Trial

Kronos Bio (KRON) Stock Price, News & Analysis

+0.16 (+12.60%)
(As of 07/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
736,930 shs
Average Volume
250,376 shs
Market Capitalization
$85.93 million
P/E Ratio
Dividend Yield
Price Target

Kronos Bio MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
188.5% Upside
$4.13 Price Target
Short Interest
1.88% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$2.79 M Bought Last Quarter
Proj. Earnings Growth
From ($1.62) to ($1.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

188th out of 915 stocks

Pharmaceutical Preparations Industry

80th out of 433 stocks

KRON stock logo

About Kronos Bio Stock (NASDAQ:KRON)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

KRON Stock Price History

KRON Stock News Headlines

There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
Kronos Bio shares target cut, retains buy rating
Kronos Bio Inc.
See More Headlines
Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$6.29 million
Book Value
$2.73 per share


Free Float
Market Cap
$85.93 million
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Norbert W. Bischofberger Ph.D.Dr. Norbert W. Bischofberger Ph.D. (Age 68)
    President, CEO & Director
    Comp: $912.2k
  • Mr. Joshua A. Kazam (Age 47)
    Co-Founder & Director
    Comp: $40k
  • Mr. David M. Tanen J.D. (Age 53)
    Secretary & Director
    Comp: $40k
  • Ms. Sandra A. Gardiner (Age 58)
    Interim CFO & Principal Accounting Officer
  • Dr. Margaux Bennett Ph.D.
    Vice President of Corporate Development & Investor Relations
  • Ms. Allison Frisbee J.D. (Age 41)
    Senior Vice President of Corporate Operations & Legal
  • Dr. Charles Lin Ph.D. (Age 39)
    Senior Vice President of Research & Development
  • Dr. Elizabeth A. Olek D.O. (Age 59)
    M.P.H., Senior Vice President of Clinical Development
  • Mr. Wes Trotter Ph.D.
    Senior Vice President of Drug Discovery & Pharmaceutical Development
  • Ms. Rocio Martin Hoyos
    Senior Vice President of Corporate Strategy & Portfolio Management

KRON Stock Analysis - Frequently Asked Questions

How have KRON shares performed this year?

Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON shares have increased by 14.4% and is now trading at $1.43.
View the best growth stocks for 2024 here

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.07. The company earned $2.52 million during the quarter, compared to analysts' expectations of $1.50 million. Kronos Bio had a negative trailing twelve-month return on equity of 68.67% and a negative net margin of 1,534.11%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRON) was last updated on 7/14/2024 by Staff

From Our Partners